Hepatocellular Carcinoma Clinical Trial
— DUET-4Official title:
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)
Verified date | March 2023 |
Source | Xencor, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.
Status | Completed |
Enrollment | 78 |
Est. completion date | February 16, 2023 |
Est. primary completion date | February 16, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: PART A (Dose Escalation Cohorts) 1. All subjects' cancer must have progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. 2. All subjects must have adequate archival tumor, or give consent to a fresh tumor biopsy. 3. Subjects have an ECOG performance status of 0-1. 4. Subjects in monotherapy and combination therapy cohorts must have histologically or cytologically confirmed advanced or metastatic solid tumors, including the following: 1. Melanoma 2. Cervical carcinoma 3. Pancreatic carcinoma 4. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (TNBC) 5. Hepatocellular carcinoma 6. Urothelial carcinoma 7. Squamous cell carcinoma of the head and neck (HNSCC) 8. Nasopharyngeal carcinoma (NPC) 9. Renal cell carcinoma 10. Colorectal carcinoma or endometrial carcinoma 11. Small cell lung carcinoma or NSCLC 12. Gastric or gastroesophageal junction adenocarcinoma 13. Prostate adenocarcinoma 14. Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer 15. Intrahepatic cholangiocarcinoma 5. Subjects in the combination cohorts in Part A with XmAb22841 and pembrolizumab may have an advanced solid tumor that either: - has progressed after treatment with all available therapies that are known to confer clinical benefit, or is intolerant or has refused standard treatment (as for the XmAb22841 monotherapy cohorts), or - is of a tumor type for which pembrolizumab is an approved indication and has not previously been treated with an agent targeting PD1 or PDL1. PART B (Dose Expansion Cohorts) XmAb22841 Single Agent Cohort 1. Must have histologically or cytologically confirmed advanced or metastatic solid tumor that has progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. Eligible tumor types include the following: 1. Anti-PD1 refractory melanoma (or any uveal melanoma) 2. Anti-PD1 refractory NSCLC 3. Anti-PD1 refractory renal cell carcinoma (with clear cell component) 4. Anti-PD1 refractory urothelial carcinoma 5. Head and neck squamous cell carcinoma 6. Hepatocellular carcinoma 7. Gastric adenocarcinoma 8. Cervical carcinoma 9. Breast carcinoma that is estrogen receptor, progesterone receptor, and HER2 negative (TNBC) 10. Epithelial ovarian cancer 11. Nasopharyngeal carcinoma 12. Squamous cell anal carcinoma 13. Squamous cell penile carcinoma 14. Squamous cell vulvar carcinoma XmAb22841 + Pembrolizumab Cohorts 1. Anti-PD-1 refractory melanoma (excluding uveal melanoma) 2. Anti-PD-1 naïve melanoma (excluding uveal melanoma) 3. Anti-PD-1 refractory NSCLC 4. Anti-PD1 naïve NSCLC a. Must be PD-L1 high (TPS = 50%), with no EGFR or ALK aberrations 5. Anti-PD1 naïve urothelial carcinoma 1. Must be PDL1 positive (CPS of = 10), or ineligible for any platinum-containing chemotherapy regardless of PDL1 status; or 2. Had disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy Exclusion Criteria: 1. Prior treatment with an investigational anti-LAG3 therapy. 2. Treatment with any CTLA4 antibody within 16 weeks of the start of study drug for Cohorts 1M, 2M, 3M, 1P, and 2P; within 8 weeks for Cohorts 4M, 5M, 3P, 4P and 4Pi; and within 3 weeks for Cohorts 6M, 7Mi, 7M, 5P, and 6P. 3. Systemic antineoplastic therapy, unconjugated antibody therapy within 4 weeks of the first dose of study treatment; or radiotherapy within 2 weeks of the first dose of study treatment; or small molecule kinase inhibitors within 6 elimination half-lives of the first dose of study treatment. 4. Have received prior therapy with an anti-PD1, anti-PDL1, or anti PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA4, OX 40, CD137) AND were permanently discontinued from that treatment due to an irAE. 5. Failure to recover from any irAE from prior cancer therapy to Grade = 1. 6. Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to Grade = 2. 7. Active known or suspected autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus; residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs). 8. Receipt of an organ allograft. 9. Treatment with antibiotics within 14 days prior to first dose of study drug. 10. Participants with known HIV. 11. Participants with known chronic hepatitis B virus (HBV) infection treated for less than 3 months prior to study enrollment and/or with a detectable HBV viral load; or hepatitis C virus (HCV) infection that has been treated for less than 4 weeks prior to study enrollment and/or with a detectable HCV viral load; or active HBV/HCV coinfection. |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan Medical School | Ann Arbor | Michigan |
United States | Emory University Hospital Midtown | Atlanta | Georgia |
United States | Winship Cancer Institute, Emory University | Atlanta | Georgia |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Brigham and Women's Health Care Center, Chestnut Hill | Chestnut Hill | Massachusetts |
United States | Mary Crowley Cancer Research - Medical City | Dallas | Texas |
United States | Karmanos Cancer Institute | Detroit | Michigan |
United States | UCSD Medical Center - Encinitas | Encinitas | California |
United States | Karmanos Cancer Institute Weisberg Cancer Treatment Center | Farmington Hills | Michigan |
United States | The University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | University of Iowa Hospital and Clinics | Iowa City | Iowa |
United States | Koman Family Outpatient Pavilion | La Jolla | California |
United States | UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) | La Jolla | California |
United States | UC San Diego Moores Cancer Center | La Jolla | California |
United States | UCSD Altman Clinical and Translational Research Institute Building (ACTRI) | La Jolla | California |
United States | UCSD Perlman Medical Offices | La Jolla | California |
United States | UCLA Hematology & Oncology Clinic | Los Angeles | California |
United States | Columbia University Medical Center | New York | New York |
United States | Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York |
United States | NYU Langone Medical Center (Tisch Hospital) | New York | New York |
United States | Hospital of the University of Pennsylvania - Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania |
United States | UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania |
United States | UPMC Shadyside Hospital | Pittsburgh | Pennsylvania |
United States | University of Utah, Huntsman Cancer Institute | Salt Lake City | Utah |
United States | UC San Diego Medical Center - Hillcrest | San Diego | California |
United States | UCSD Rancho Bernardo Medical Office | San Diego | California |
United States | UCSD Medical Center - Vista | Vista | California |
Lead Sponsor | Collaborator |
---|---|
Xencor, Inc. | ICON Clinical Research |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03. | Rates of treatment-related adverse events (AEs), graded by CTCAE v4.03, and additionally categorized as either immune-related or non-immune AEs. | 56 Days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |